ROLE OF CFH AND ARMS2 POLYMORPHISMS IN RETINOPATHY AND CORANARY ARTERY DISEASE IN TYPE 1 DIABETES
DOI:
https://doi.org/10.23938/ASSN.0098Keywords:
Diabetes tipo 1. Retinopatía diabética proliferativa. Cardiopatía isquémica. CFH. ARMS2.Abstract
Background. Type 1 diabetes is associated with vascular morbidity. The aim of this study was to evaluate the role of polymorphisms rs1410996 CFH and rs10490924 ARMS2 with proliferative diabetic retinopathy and coronary disease in type 1 diabetes patients . Material and methods. We present a retrospective study that analyses the clinical characteristics and the polymorphisms rs1410996 CFH and rs10490924 ARMS2 of 147 type 1 diabetes patients. Results. The patients who developed proliferative diabetic retinopathy in the first 20 years carried the rs1410996 CFH polymorphism. The overall risk-allele frequency was significantly higher among patients with coronary artery disease than in those without it (75 vs 53%, p<0.001). Conclusions. rs1410996 CFH polymorphism could be associated with both proliferative diabetic retinopathy and coronary artery disease in type 1 diabetes patients. However, rs10490924 ARMS2 does not seem to be associated either with retinopathy or coronary artery disease.Downloads
References
1. GEORGE S. EISENBARTH. Diabetes mellitus tipo 1. En: Kahn CR, Weir GC, King GL, Jacobson AL, Moses AC, Smith RJ, editors. Joslin's Diabetes Mellitus, Massachusets: Boston, 2007: 399-424.
2. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. American Diabetes Association, Alexandria, Virginia, USA. Report of expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003; 26 (Suppl.1): S5-S20.
https://doi.org/10.2337/diacare.26.2007.S5
3. GODAY A, CALTELL C, TRESSERRAS JL, LLOVERAS G. La diabetes mellitus tipo 1 en España. Estimación de la incidencia anual y su distribución por Comunidades Autónomas y provincias. Endocrinología 1994; 41: 301-304.
4. RUIZ-RAMOS M, ESCOLAR-PUJOLAR A, MAYORAL-SÁNCHEZ E, CORRAL-SAN LAUREANO F, FERNÁNDEZ-FERNÁNDEZ I. Mellitus diabetes in Spain: death rates, prevalence, impact, costs and inequalities. Gac Sanit 2006; 20 (Suppl. 1): 15-24.
https://doi.org/10.1157/13086022
5. SIBAL L, LAW HN, GEBBIE J, DASHORA UK, AGARWAL SC, HOME P. Predicting the development of macrovascular disease in people with type 1 diabetes: A 9-year follow-up study. Ann N Y Acad Sci 2006; 1084: 191-207.
https://doi.org/10.1196/annals.1372.037
6. CUSICK M, MELETH AD, AGRON E, FISHER MR, REED GF, KNATTERUD GL et al. Associations of mortality and diabetes complications in patients with type 1 and type 2 diabetes: early treatment diabetic retinopathy study report no. 27. Diabetes Care 2005; 28: 617-625.
https://doi.org/10.2337/diacare.28.3.617
7. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-986.
https://doi.org/10.1056/NEJM199309303291401
8. ORCHARD TJ, COSTACOU T, KRETOWSKI A, NESTO RW. Type 1 diabetes and coronary artery disease. Diabetes Care 2006; 29: 2528-2538.
https://doi.org/10.2337/dc06-1161
9. The diabetes control and complications trial/epidemiology of diabetes interventions and complications research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000; 342: 381-389.
https://doi.org/10.1056/NEJM200002103420603
10. FRITSCHE LG, LOENHARDT T, JANSSEN A, FISHER SA, RIVERA A, KEILHAUER CN et al. Age-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA. Nat Genet 2008; 40: 892-896.
https://doi.org/10.1038/ng.170
11. MALLER J, GEORGE S, PURCELL S, FAGERNESS J, ALTSHULER D, DALY MJ et al. Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration. Nat Genet 2006; 38: 1055-1059.
https://doi.org/10.1038/ng1873
12. AANDONEGUI J, SERRANO L, EGÚZKIZA A. eOftalmología: estado actual y tendencias futuras. An Sist Sanit Navar 2010; 33: 79-91.
https://doi.org/10.4321/S1137-66272010000100009
13. FORGA L. Retinografía no midriática para la detección de la retinopatía diabética. Un ejemplo de adaptación al medio. An Sist Sanit Navar 2010; 33: 255-258.
https://doi.org/10.4321/S1137-66272010000400001
14. GIBELALDE A, RUIZ-MIGUEL M, MENDICUTE J, AYERDI S, MARTÍNEZ-ZABALEGI D. Prevalencia de retinopatía diabética mediante cribado con retinógrafo no midriático. An Sist Sanit Navar 2010; 33: 271-276.
https://doi.org/10.4321/S1137-66272010000400003
15. DONEY AS, LEESE GP, OLSON J, MORRIS AD, PALMER CN. The Y402H variant of complement factor H is associated with age-related macular degeneration but not with diabetic retinal disease in the Go-DARTS study. Diabet Med 2009; 26: 460-465.
https://doi.org/10.1111/j.1464-5491.2009.02719.x
16. KARDYS I, KLAVER CC, DESPRIET DD, BERGEN AA, UITTERLINDEN AG, HOFMAN A et al. A common polymorphism in the complement factor H gene is associated with increased risk of myocardial infarction: the Rotterdam Study. J Am Coll Cardiol 2006; 47: 1568-1575.
https://doi.org/10.1016/j.jacc.2005.11.076
17. KOSHY A, GIACHERIO D, HAYWARD R. Hemoglobin A1c Fact Sheet.U-M MDRTC Chemistry Laboratory.
18. Grupo de Trabajo para el manejo del síndrome coronario agudo (SCA) en pacientes sin elevación persistente del segmento ST de la Sociedad Europea de Cardiología (ESC). Autores/Miembros del Grupo de Trabajo: Christian W. Hamm (Moderador) (Alemania), Jean-Pierre Bassand(Co-Moderador), (Francia), Stefan Agewall (Noruega), Jeroen Bax (Paises Bajos), Eric Boersma (Paises Bajos), Hector Bueno (Espana), Pio Caso (Italia), Dariusz Dudek (Polonia), Stephan Gielen (Alemania), Kurt Huber (Austria), Magnus Ohman (Estados Unidos), Mark C. Petrie (Reino Unido),Frank Sonntag (Alemania), Miguel Sousa Uva (Portugal), Robert F. Storey (Reino Unido), William Wijns (Belgica) y Doron Zahger (Israel). Guía de practica clínica de la ESC para el manejo del síndrome coronario agudo en pacientes sin elevación persistente del segmento ST. Rev Esp Cardiol. 2012; 65: 173. e1-e55.
https://doi.org/10.1016/j.recesp.2011.11.006
19. ALISEDA D, BERASTEGUI L. Retinopatía diabética. An Sist Sanit Navar 2008; 31 (Supl. 3): 23-34.
https://doi.org/10.4321/S1137-66272008000600003
20. MONTES R, RUIZ DE GAONA E, MARTÍNEZ-GONZÁLEZ MA, ALBERCA I, HERMIDA J. The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients. Br J Haematol 2006; 133: 183-187.
https://doi.org/10.1111/j.1365-2141.2006.06007.x
21. GERL VB, BOHL J, PITZ S, STOFFELNS B, PFEIFFER N, BHAKDI S. Extensive deposits of complement C3d and C5b-9 in the choriocapillaries of eyes of patients with diabetic retinopathy. Invest Ophthalmol Vis Sci 2002; 43: 1104-1108.
22. ZHANG J, GERHARDINGER C, LORENZI M. Early complement activation and decreased levels of glycosylphosphatidylinositol-anchored complement inhibitors in human and experimental diabetic retinopathy. Diabetes 2002; 51: 3499-3504.
https://doi.org/10.2337/diabetes.51.12.3499
23. NICAUD V, FRANCOMME C, RUIDAVETS JB, LUC G, ARVEILER D, KEE F, et al. Lack of association between complement factor H polymorphism and coronary artery disease or myocardial infarction. J Mol Med 2007; 85: 771-775.
https://doi.org/10.1007/s00109-007-0185-2
24. PAI JK, MANSON JE, REXRODE KM, ALBERT CM, HUNTER DJ, RIMM EB. Complement factor H (Y402H) polymorphism and risk of coronary heart disease in US men and women. Eur Heart J 2007; 28: 1297-1303.
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
